Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results
Authors:
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 103 (3) , 137-143
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
- Novo Nordisk
- Allergan
- Shionogi
- New England Research Institutes
- American Regent
- Merck
- Bayer HealthCare
- Pfizer
- Astellas Pharma US
- Abbott Laboratories
- Aileron Therapeutics (NCT02158572)
This publication has 11 references indexed in Scilit:
- Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trialsThe Lancet Global Health, 2019
- Pregnancy Intention and Contraceptive Use among Women by Class of Obesity: Results from the 2006–2010 and 2011–2013 National Survey of Family GrowthWomen's Health Issues, 2018
- Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysisContraception, 2015
- Transdermal contraception methods: today’s patches and new options on the horizonExpert Opinion on Pharmacotherapy, 2015
- Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptiveContraception, 2014
- Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysisBMJ, 2013
- Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trialContraception, 2012
- Predictors of noncompliance in an oral contraceptive clinical trialContraception, 2012
- Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutationsBritish Journal of Haematology, 2007
- Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study resultsContraception, 2006